[1]
|
Su, D., Zhu, S., Han, X., Feng, Y., Huang, H., Ren, G., Pan, L., Zhang, Y., Lu, J. and Huang, B. (2009) BMP4-Smad Signaling Pathway Mediates Adriamycin-Induced Premature Senescence in Lung Cancer Cells. The Journal of Biological Chemistry, 284, 12153-12164. https://doi.org/10.1074/jbc.M807930200
|
[2]
|
Chen, J.Y. and Stubbe, J. (2005) Bleomycins: Towards Better Therapeutics. Nature Reviews. Cancer, 5, 102-112.
https://doi.org/10.1038/nrc1547
|
[3]
|
Qiu, T., Tian, Y., Gao, Y., Ma, M., Li, H., Liu, X., Wu, H., et al. (2019) PTEN Loss Regulates Alveolar Epithelial Cell Senescence in Pulmonary Fibrosis Depending on Akt Activation. Aging, 11, 7492-7509.
https://doi.org/10.18632/aging.102262
|
[4]
|
Aoshiba, K., Tsuji, T. and Nagai, A. (2003) Bleomycin Induces Cellu-lar Senescence in Alveolar Epithelial Cells. The European Respiratory Journal, 22, 436-443. https://doi.org/10.1183/09031936.03.00011903
|
[5]
|
Pack, L.R., Daigh, L.H., Chung, M.Y. and Meyer, T. (2021) Clinical CDK4/6 Inhibitors Induce Selective and Immediate Dissociation of p21 from Cyclin D-CDK4 to Inhibit CDK2. Nature Communications, 12, Article No. 3356.
https://doi.org/10.1038/s41467-021-23612-z
|
[6]
|
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D. and Barbacid, M. (2010) A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-Small Cell Lung Carcinoma. Cancer Cell, 18, 63-73. https://doi.org/10.1016/j.ccr.2010.05.025
|
[7]
|
Daifuku, R., Hu, Z.B. and Saunthararajah, Y. (2017) 5-aza-2’,2’-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonu-cleotide Reductase Inhibitor for the Treatment of Cancer. Pharmaceuticals, 10, Article No. 65. https://doi.org/10.3390/ph10030065
|
[8]
|
Amatori, S., Bagaloni, I., Viti, D. and Fanelli, M. (2011) Premature Se-nescence Induced by DNA Demethylating Agent (Decitabine) as Therapeutic Option for Malignant Pleural Mesothelioma. Lung Cancer, 71, 113-115.
https://doi.org/10.1016/j.lungcan.2010.10.016
|
[9]
|
Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., West-man, E.A., Caldwell, S.D., Napper, A., et al. (2005) Substrate-Specific Activation of Sirtuins by Resveratrol. The Jour-nal of Biological Chemistry, 280, 17038-17045.
https://doi.org/10.1074/jbc.M500655200
|
[10]
|
Ota, H., Tokunaga, E., Chang, K., Hikasa, M., Iijima, K., Eto, M., Kozaki, K., Akishita, M., Ouchi, Y. and Kaneki, M. (2006) Sirt1 Inhibitor, Sirtinol, Induces Senescence-Like Growth Arrest with Attenuated Ras-MAPK Signaling in Human Cancer Cells. Oncogene, 25, 176-185. https://doi.org/10.1038/sj.onc.1209049
|
[11]
|
Cacioppo, R. and Lindon, C. (2022) Regulating the Regulator: A Sur-vey of Mechanisms from Transcription to Translation Controlling Expression of Mammalian Cell Cycle Kinase Aurora A. Open Biology, 12, Article ID: 220134.
https://doi.org/10.1098/rsob.220134
|
[12]
|
Wang, L.Q., de Oliveira, R.L., Wang, C., Fernandes Neto, J.M., Mainardi, S., Evers, B., Lieftink, C., et al. (2017) High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer. Cell Reports, 21, 773-783. https://doi.org/10.1016/j.celrep.2017.09.085
|
[13]
|
Szlachta, K., Kuscu, C., Tufan, T., Adair, S.J., Shang, S., Michaels, A.D., Mullen, M.G., et al. (2018) CRISPR Knockout Screening Identifies Combinatorial Drug Targets in Pancreatic Cancer and Models Cellular Drug Response. Nature Communications, 9, Article No. 4275. https://doi.org/10.1038/s41467-018-06676-2
|
[14]
|
Van den Bossche, J., Deben, C., De Pauw, I., Lambrechts, H., Hermans, C., De-schoolmeester, V., Jacobs, J., et al. (2019) In Vitro Study of the Polo-Like Kinase 1 Inhibitor Volasert-ib in Non-Small-Cell Lung Cancer Reveals a Role for the Tumor Suppressor P53. Molecular Oncology, 13, 1196-1213. https://doi.org/10.1002/1878-0261.12477
|
[15]
|
Hou, Q., Jiang, Z., Li, Y., Wu, H., Yu, J. and Jiang, M. (2020) FAM60A Promotes Cisplatin Resistance in Lung Cancer Cells by Activating SKP2 Expression. Anti-Cancer Drugs, 31, 776-784.
https://doi.org/10.1097/CAD.0000000000000952
|
[16]
|
Liu, J., Zheng, X., Li, W., Ren, L., Li, S., Yang, Y., Yang, H., et al. (2022) Anti-Tumor Effects of Skp2 Inhibitor AAA-237 on NSCLC by Arresting Cell Cycle at G0/G1 Phase and Inducing Senescence. Pharmacological Research, 181, Article ID: 106259. https://doi.org/10.1016/j.phrs.2022.106259
|
[17]
|
Huang, T., Yang, L., Wang, G., Ding, G., Peng, B., Wen, Y. and Wang, Z. (2017) Inhibition of Skp2 Sensitizes Lung Cancer Cells to Paclitaxel. OncoTargets and Therapy, 10, 439-446. https://doi.org/10.2147/OTT.S125789
|
[18]
|
Huo, K.G., Notsuda, H., Fang, Z., Liu, N.F., Gebregiworgis, T., Li, Q., Pham, N.A., et al. (2022) Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 17, 277-288.
https://doi.org/10.1016/j.jtho.2021.09.008
|
[19]
|
Tian, Y.T., Ma, L.P., Ding, C.Y., Liu, M.M., Wang, S.N., Tian, M., Gao, L. and Liu, Q.J. (2022) Autophagy Regulates X-Ray Radiation-Induced Premature Senescence through STAT3-Beclin1-P62 Pathway in Lung Adenocarcinoma Cells. International Journal of Radiation Biology, 98, 1432-1441. https://doi.org/10.1080/09553002.2022.2055799
|
[20]
|
Patil, S., Reedy, J.L., Scroggins, B.T., White, A.O., Kwon, S., Shankavaram, U., López-Coral, A., Chung, E.J. and Citrin, D.E. (2022) Senescence-Associated Tumor Growth Is Promoted by 12-Lipoxygenase. Aging, 14, 1068-1086.
https://doi.org/10.18632/aging.203890
|
[21]
|
Guo, Y.-J., Pan, W.-W., Liu, S.-B., Shen, Z.-F., Xu, Y. and Hu, L.-L. (2020) ERK/MAPK Signalling Pathway and Tumorigenesis. Experimental and Therapeutic Medicine, 19, 1997-2007. https://doi.org/10.3892/etm.2020.8454
|
[22]
|
Odogwu, L., Mathieu, L., Blumenthal, G., Larkins, E., Goldberg, K.B., Griffin, N., Bijwaard, K., et al. (2018) FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Meta-static Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. The Oncologist, 23, 740-745. https://doi.org/10.1634/theoncologist.2017-0642
|
[23]
|
Ruscetti, M., Leibold, J., Bott, M.J., Fennell, M., Kulick, A., Salgado, N.R., Chen, C.-C., et al. (2018) NK Cell-Mediated Cytotoxicity Contributes to Tumor Control by a Cytostatic Drug Combination. Science (New York, N.Y.), 362, 1416-1422. https://doi.org/10.1126/science.aas9090
|
[24]
|
Haston, S., Gonzalez-Gualda, E., Morsli, S., Ge, J.F., Reen, V., Calderwood, A., Moutsopoulos, I., et al. (2023) Clearance of Senescent Macrophages Ameliorates Tumorigenesis in KRAS-Driven Lung Cancer. Cancer Cell, 41, 1242-1260.e6.
https://doi.org/10.1016/j.ccell.2023.05.004
|
[25]
|
Jochems, F., Thijssen, B., De Conti, G., Jansen, R., Pogacar, Z., Groot, K., Wang, L.Q., et al. (2021) The Cancer SENESCopedia: A Delineation of Cancer Cell Senescence. Cell Reports, 36, Article ID: 109441.
https://doi.org/10.1016/j.celrep.2021.109441
|
[26]
|
Tan, N., Malek, M., Zha, J.P., Yue, P., Kassees, R., Berry, L., Fairbrother, W.J., Sampath, D. and Belmont, L.D. (2011) Navitoclax Enhances the Efficacy of Taxanes in Non-Small Cell Lung Cancer Models. Clinical Cancer Research, 17, 1394-1404. https://doi.org/10.1158/1078-0432.CCR-10-2353
|
[27]
|
Sun, L., Morikawa, K., Sogo, Y. and Sugiura, Y. (2021) MHY1485 Enhances X-Irradiation-Induced Apoptosis and Senescence in Tumor Cells. Journal of Radiation Research, 62, 782-792. https://doi.org/10.1093/jrr/rrab057
|
[28]
|
Arrieta, O., Barrón, F., Padilla, M.S., Avilés-Salas, A., Ramírez-Tirado, L.A., Arguelles Jiménez, M.J., Vergara, E., et al. (2019) Effect of Metformin plus Tyrosine Kinase In-hibitors Compared with Tyrosine Kinase Inhibitors Alone in Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncology, 5, e192553. https://doi.org/10.1001/jamaoncol.2019.2553
|
[29]
|
Chen, H., Lin, C., Lu, C., Wang, Y., Han, R., Li, L., Hao, S. and He, Y. (2019) Metformin-Sensitized NSCLC Cells to Osimertinib via AMPK-Dependent Autophagy Inhibition. The Clinical Respiratory Journal, 13, 781-790.
https://doi.org/10.1111/crj.13091
|
[30]
|
Chen, H., Lin, C., Peng, T., Hu, C., Lu, C., Li, L., Wang, Y., et al. (2020) Metformin Reduces HGF-Induced Resistance to Alectinib via the Inhibition of Gab1. Cell Death & Disease, 11, Article No. 111.
https://doi.org/10.1038/s41419-020-2307-5
|
[31]
|
Li, L., Jiang, L., Wang, Y., Zhao, Y., Zhang, X.J., Wu, G., Zhou, X., et al. (2019) Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Pa-tients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25, 6967-6975. https://doi.org/10.1158/1078-0432.CCR-19-0437
|
[32]
|
Afzal, M.Z., Dragnev, K., Sarwar, T. and Shirai, K. (2019) Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors. Lung Cancer Management, 8, LMT11.
https://doi.org/10.2217/lmt-2018-0016
|
[33]
|
Wang, J.L., Lan, Y.W., Tsai, Y.T., Chen, Y.C., Staniczek, T., Tsou, Y.A., Yen, C.C. and Chen, C.M. (2021) Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model. Frontiers in Cell and Developmental Biology, 9, Article ID: 688062.
https://doi.org/10.3389/fcell.2021.688062
|
[34]
|
Riaz, M.A., Sak, A., Erol, Y.B., Groneberg, M., Thomale, J. and Stuschke, M. (2019) Metformin Enhances the Radiosensitizing Effect of Cisplatin in Non-Small Cell Lung Cancer Cell Lines with Different Cisplatin Sensitivities. Scientific Reports, 9, Article No. 1282. https://doi.org/10.1038/s41598-018-38004-5
|
[35]
|
Salmani-Javan, E., Jafari-Gharabaghlou, D., Bonabi, E. and Zarghami, N. (2023) Fabricating Niosomal-PEG Nano-Particles Co-Loaded with Metformin and Silibinin for Effective Treatment of Human Lung Cancer Cells. Frontiers in Oncology, 13, Article ID: 1193708. https://doi.org/10.3389/fonc.2023.1193708
|
[36]
|
Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., et al. (2019) Identification and Characterization of Cardiac Glycosides as Senolytic Compounds. Nature Communications, 10, Article No. 4731. https://doi.org/10.1038/s41467-019-12888-x
|
[37]
|
Guerrero, A., Herranz, N., Sun, B., Wagner, V., Gallage, S., Guiho, R., Wolter, K., et al. (2019) Cardiac Glycosides Are Broad-Spectrum Senolytics. Nature Metabolism, 1, 1074-1088. https://doi.org/10.1038/s42255-019-0122-z
|
[38]
|
Deryabin, P.I., Shatrova, A.N. and Borodkina, A.V. (2021) Apoptosis Resistance of Senescent Cells Is an Intrinsic Barrier for Senolysis Induced by Cardiac Glycosides. Cellular and Molecular Life Sciences: CMLS, 78, 7757-7776.
https://doi.org/10.1007/s00018-021-03980-x
|
[39]
|
Meng, Z., Yang, P., Shen, Y., Bei, W., Zhang, Y., Ge, Y., Newman, R.A., et al. (2009) Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Nonsmall-Cell Lung Cancer, or Pancreatic Cancer. Cancer, 115, 5309-5318.
https://doi.org/10.1002/cncr.24602
|
[40]
|
Zhang, C. and Fu, L. (2017) Effects of Bufalin Combined with Doxorubi-cin on the Proliferation and Apoptosis of Human Lung Cancer Cell Line A549 in Vitro. Journal of Central South Uni-versity. Medical Sciences, 42, 762-768.
|
[41]
|
Kang, X.-H., Gong, Y.-B., Wang, L.-F., Wang, Z.-Q., Deng, H.-B., Zhao, X.-Z., Wu, J. and Xu, Z.-Y. (2013) Effect of Bufalin Combined Gefitinib on Lung Cancer H1975 Cells and Its Mecha-nisms Research. Chinese Journal of Integrated Traditional and Western Medicine, 33, 1081-1085.
|
[42]
|
Huang, A.C., Yang, M.D., Hsiao, Y.T., Lin, T.S., Ma, Y.S., Peng, S.F., Hsia, T.C., Cheng, Y.D., Kuo, C.L. and Chung, J.G. (2016) Bufalin Inhibits Gefitinib Resistant NCI-H460 Human Lung Cancer Cell Migration and Invasion in Vitro. Journal of Ethnopharmacology, 194, 1043-1050. https://doi.org/10.1016/j.jep.2016.11.004
|
[43]
|
Cao, F., Gong, Y.B., Kang, X.H., Lu, Z., Wang, Y., Zhao, K.L., Miao, Z., Liao, M.J. and Xu, Z.Y. (2019) Degradation of MCL-1 by Bufalin Re-verses Acquired Resistance to Osimertinib in EGFR-Mutant Lung Cancer. Toxicology and Applied Pharmacology, 379, Article ID: 114662. https://doi.org/10.1016/j.taap.2019.114662
|
[44]
|
Kuo, J.Y., Liao, C.L., Ma, Y.S., Kuo, C.L., Chen, J.C., Huang, Y.P., Huang, W.W., Peng, S.F. and Chung, J.G. (2022) Combination Treatment of Sorafenib and Bufalin Induces Apoptosis in NCI-H292 Human Lung Cancer Cells in Vitro. In Vivo (Athens, Greece), 36, 582-595. https://doi.org/10.21873/invivo.12741
|
[45]
|
Liu, M., Feng, L.X., Sun, P., Liu, W., Wu, W.Y., Jiang, B.H., Yang, M., Hu, L.H., Guo, D.A. and Liu, X. (2016) A Novel Bufalin Derivative Exhibited Stronger Apoptosis-Inducing Effect than Bufalin in A549 Lung Cancer Cells and Lower Acute Toxicity in Mice. PLOS ONE, 11, e0159789. https://doi.org/10.1371/journal.pone.0159789
|
[46]
|
Chen, Q. and Liu, J. (2018) Transferrin and Folic Acid Co-Modified Bufalin-Loaded Nanoliposomes: Preparation, Characterization, and Application in Anticancer Activity. In-ternational Journal of Nanomedicine, 13, 6009-6018.
https://doi.org/10.2147/IJN.S176012
|
[47]
|
Han, Y., Ma, R., Cao, G., Liu, H., He, L., Tang, L., Li, H. and Luo, Q. (2021) Combined Treatment of Cinobufotalin and Gefitinib Exhibits Potent Efficacy against Lung Cancer. Evi-dence-Based Complementary and Alternative Medicine: eCAM, 2021, Article ID: 6612365. https://doi.org/10.1155/2021/6612365
|
[48]
|
Liao, Y.C., Shih, Y.W., Chao, C.H., Lee, X.Y. and Chiang, T.A. (2009) Involvement of the ERK Signaling Pathway in Fisetin Reduces Invasion and Migration in the Human Lung Cancer Cell Line A549. Journal of Agricultural and Food Chemistry, 57, 8933-8941. https://doi.org/10.1021/jf902630w
|
[49]
|
Tabasum, S. and Singh, R.P. (2019) Fisetin Suppresses Migration, Inva-sion and Stem-Cell-Like Phenotype of Human Non-Small Cell Lung Carcinoma Cells via Attenuation of Epithelial to Mesenchymal Transition. Chemico-Biological Interactions, 303, 14-21. https://doi.org/10.1016/j.cbi.2019.02.020
|
[50]
|
Ganthala, P.D., Alavala, S., Chella, N., Andugulapati, S.B., Bathini, N.B. and Sistla, R. (2022) Co-Encapsulated Nanoparticles of Erlotinib and Quercetin for Targeting Lung Cancer through Nuclear EGFR and PI3K/AKT Inhibition. Colloids and Surfaces B, Biointerfaces, 211, Article ID: 112305. https://doi.org/10.1016/j.colsurfb.2021.112305
|
[51]
|
Sabarwal, A., van Rooyen, J.C., Caburet, J., Avgenikos, M., Dheeraj, A., Ali, M., Mishra, D., et al. (2022) A Novel 4’-Brominated Derivative of Fisetin Induces Cell Cycle Arrest and Apoptosis and Inhibits EGFR/ERK1/2/STAT3 Pathways in Non-Small-Cell Lung Cancer without Any Adverse Ef-fects in Mice. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 36, e22654.
https://doi.org/10.1096/fj.202200669RR
|
[52]
|
De Marinis, F., Atmaca, A., Tiseo, M., Giuffreda, L., Rossi, A., Gebbia, V., D’Antonio, C., et al. (2013) A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer. Journal of Thoracic Oncology: Official Publication of the Interna-tional Association for the Study of Lung Cancer, 8, 1091-1094. https://doi.org/10.1097/JTO.0b013e318293d88c
|
[53]
|
Zhu, L., Wu, K., Ma, S. and Zhang, S. (2015) HDAC Inhib-itors: A New Radiosensitizer for Non-Small-Cell Lung Cancer. Tumori Journal, 101, 257-262. https://doi.org/10.5301/tj.5000347
|
[54]
|
Hs, T., Singhal, N., Gowda, R., Penniment, M., Takhar, P. and Brown, M.P. (2015) Phase I Study Evaluating the Safety and Efficacy of Oral Panobinostat in Combination with Radiotherapy or Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer. Anti-Cancer Drugs, 26, 1069-1077.
https://doi.org/10.1097/CAD.0000000000000282
|
[55]
|
Fischer, C., Leithner, K., Wohlkoenig, C., Quehenberger, F., Bertsch, A., Olschewski, A., Olschewski, H. and Hrzenjak, A. (2015) Panobinostat Reduces Hypoxia-Induced Cisplatin Resistance of Non-Small Cell Lung Carcinoma Cells via HIF-1α Destabilization. Molecular Cancer, 14, Article No. 4. https://doi.org/10.1186/1476-4598-14-4
|
[56]
|
Wang, L., Syn, N.L., Subhash, V.V., Any, Y., Thuya, W.L., Cheow, E.S.H., Kong, L., et al. (2018) Pan-HDAC Inhibition by Panobinostat Mediates Chemosensitization to Carboplatin in Non-Small Cell Lung Cancer via Attenuation of EGFR Signaling. Cancer Letters, 417, 152-160. https://doi.org/10.1016/j.canlet.2017.12.030
|
[57]
|
Greve, G., Schiffmann, I., Pfeifer, D., Pantic, M., Schüler, J. and Lübbert, M. (2015) The Pan-HDAC Inhibitor Panobinostat Acts as a Sensitizer for Erlotinib Activity in EGFR-Mutated and -Wildtype Non-Small Cell Lung Cancer Cells. BMC Cancer, 15, Article No. 947. https://doi.org/10.1186/s12885-015-1967-5
|
[58]
|
Peter, R.M., Sarwar, M.S., Mostafa, S.Z., Wang, Y., Su, X. and Kong, A.N. (2023) Histone Deacetylase Inhibitor Belinostat Regulates Metabolic Reprogramming in Killing KRAS-Mutant Human Lung Cancer Cells. Molecular Carcinogenesis, 62, 1136-1146. https://doi.org/10.1002/mc.23551
|
[59]
|
Nakajima, W., Sharma, K., Hicks, M.A., Le, N., Brown, R., Krystal, G.W. and Harada, H. (2016) Combination with Vorinostat Overcomes ABT-263 (Navitoclax) Resistance of Small Cell Lung Cancer. Cancer Biology & Therapy, 17, 27-35. https://doi.org/10.1080/15384047.2015.1108485
|
[60]
|
González-Gualda, E., Pàez-Ribes, M., Lozano-Torres, B., Macias, D., et al. (2020) Galacto-Conjugation of Navitoclax as an Efficient Strategy to Increase Senolytic Specificity and Reduce Plate-Let Toxicity. Aging Cell, 19, e13142.
https://doi.org/10.1111/acel.13142
|
[61]
|
Khan, S., Kellish, P., Connis, N., Thummuri, D., Wiegand, J., Zhang, P., Zhang, X., et al. (2023) Co-Targeting BCL-XL and MCL-1 with DT2216 and AZD8055 Synergistically Inhibit Small-Cell Lung Cancer Growth without Causing On-Target Toxicities in Mice. Cell Death Discovery, 9, Article No. 1.
https://doi.org/10.1038/s41420-022-01296-8
|
[62]
|
Kaiser, M., Semeraro, M.D., Herrmann, M., Absenger, G., Gerger, A. and Renner, W. (2021) Immune Aging and Immunotherapy in Cancer. International Journal of Molecular Sciences, 22, Article No. 7016.
https://doi.org/10.3390/ijms22137016
|
[63]
|
Ohtani, N. (2019) Deciphering the Mechanism for Induction of Senes-cence-Associated Secretory Phenotype (SASP) and Its Role in Aging and Cancer Development. Journal of Biochemistry, 166, 289-295.
https://doi.org/10.1093/jb/mvz055
|